NK-Cell Engagers in Cancer Immunotherapy: Recent Advances, Translational Challenges, and Future Strategies
Priorities include matching engager design to tumor and effector biology, optimizing pharmacokinetic and pharmacodynamic properties, defining predictive biomarkers, and developing rational combinations that translate early responses into durable disease control.